Emma S Scott1,2, Andrzej S Januszewski1, Rachel O'Connell1, Gregory Fulcher2,3, Russell Scott4, Antero Kesaniemi5, Linda Wu1,2, Stephen Colagiuri6, Anthony Keech1, Alicia J Jenkins1. 1. National Health and Medical Research Council (NHMRC) Clinical Trial Centre, University of Sydney, Sydney, Australia. 2. Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia. 3. Northern Clinical School, University of Sydney, Sydney, Australia. 4. Canterbury District Health Board, Christchurch, New Zealand. 5. Oulu Medical Research Centre, University of Oulu and Oulu University Hospital, Oulu, Finland. 6. The Boden Institute, University of Sydney, Sydney, Australia.
Abstract
AIMS: To investigate whether long-term glycemic variability (GV) is associated with vascular complication development in type 2 diabetes. METHODS: In a post hoc FIELD trial analysis, GV was calculated as the standard deviation and coefficient of variation (CV) of glycated hemoglobin A1c (HbA1c) and fasting plasma glucose. Baseline variables were compared across quartiles of on-study variability by chi square and ANOVA. Prospective associations between baseline to 2-year GV and subsequent vascular and mortality outcomes were analyzed using landmark logistic and Cox proportional hazards regression. RESULTS: Baseline factors associated with higher on-study GV included younger age, male gender, longer diabetes duration, and higher pharmacological therapies usage. Both HbA1c and fasting glucose CV were associated with increased risk of microvascular complications (HR 1.02 [95% CI, 1.01-1.03] P < 0.01; and HR 1.01 [95% CI, 1.00-1.01] P < 0.001, respectively). HbA1c and fasting glucose CV were associated with increased cardiovascular disease (HR 1.02 [95% CI, 1.00-1.04]; and HR 1.01 [95% CI, 1.00-1.02], both P < 0.05). HbA1c CV associated with increased stroke (HR 1.03 [95% CI, 1.01-1.06) P < 0.01). Glucose CV associated with increased coronary events (HR 1.01 [95% CI, 1.00-1.02] P < 0.05). Both HbA1c and glucose CV associated with increased total mortality (HR 1.04 [95% CI, 1.02-1.06]; and HR 1.01 [95% CI, 1.01-1.02], both P < 0.001) and noncardiovascular mortality (HR 1.05 [95% CI, (1.03-1.07]; and HR 1.02 [95% CI, 1.01-1.03], both P < 0.001). HbA1c CV associated with coronary mortality (HR 1.04 [95% CI, 1.01-1.07] P < 0.05). CONCLUSIONS: Long-term GV was associated with increased risk of vascular outcomes in type 2 diabetes. Published by Oxford University Press on behalf of the Endocrine Society 2020.
AIMS: To investigate whether long-term glycemic variability (GV) is associated with vascular complication development in type 2 diabetes. METHODS: In a post hoc FIELD trial analysis, GV was calculated as the standard deviation and coefficient of variation (CV) of glycated hemoglobin A1c (HbA1c) and fasting plasma glucose. Baseline variables were compared across quartiles of on-study variability by chi square and ANOVA. Prospective associations between baseline to 2-year GV and subsequent vascular and mortality outcomes were analyzed using landmark logistic and Cox proportional hazards regression. RESULTS: Baseline factors associated with higher on-study GV included younger age, male gender, longer diabetes duration, and higher pharmacological therapies usage. Both HbA1c and fasting glucose CV were associated with increased risk of microvascular complications (HR 1.02 [95% CI, 1.01-1.03] P < 0.01; and HR 1.01 [95% CI, 1.00-1.01] P < 0.001, respectively). HbA1c and fasting glucose CV were associated with increased cardiovascular disease (HR 1.02 [95% CI, 1.00-1.04]; and HR 1.01 [95% CI, 1.00-1.02], both P < 0.05). HbA1c CV associated with increased stroke (HR 1.03 [95% CI, 1.01-1.06) P < 0.01). Glucose CV associated with increased coronary events (HR 1.01 [95% CI, 1.00-1.02] P < 0.05). Both HbA1c and glucose CV associated with increased total mortality (HR 1.04 [95% CI, 1.02-1.06]; and HR 1.01 [95% CI, 1.01-1.02], both P < 0.001) and noncardiovascular mortality (HR 1.05 [95% CI, (1.03-1.07]; and HR 1.02 [95% CI, 1.01-1.03], both P < 0.001). HbA1c CV associated with coronary mortality (HR 1.04 [95% CI, 1.01-1.07] P < 0.05). CONCLUSIONS: Long-term GV was associated with increased risk of vascular outcomes in type 2 diabetes. Published by Oxford University Press on behalf of the Endocrine Society 2020.
Entities:
Keywords:
type 2 diabetes; HbA1c coefficient of variation; cardiovascular disease; glucose coefficient of variation; glycemic variability; stroke; vascular complications
Authors: Shaik Sarfaraz Nawaz; Khalid Siddiqui; Muhammad Mujammami; Obeed Alotaibi; Saud Sulaiman Alanazi; Mohamed Rafiullah Journal: Int J Gen Med Date: 2022-04-27
Authors: Antonio Ceriello; Giuseppe Lucisano; Francesco Prattichizzo; Rosalba La Grotta; Stefan Franzén; Ann-Marie Svensson; Björn Eliasson; Antonio Nicolucci Journal: Cardiovasc Diabetol Date: 2022-01-24 Impact factor: 9.951
Authors: Sharen Lee; Jiandong Zhou; Keith Sai Kit Leung; William Ka Kei Wu; Wing Tak Wong; Tong Liu; Ian Chi Kei Wong; Kamalan Jeevaratnam; Qingpeng Zhang; Gary Tse Journal: BMJ Open Diabetes Res Care Date: 2021-06